Global Biological Safety Testing Products and Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Biological Safety Testing Products and Services Market Overview

The Biological Safety Testing Products and Services Market was valued at USD 5.84 billion in 2025 and is projected to reach USD 14.66 billion by 2033, growing at a CAGR of 12.20% from 2026 to 2033. The market is witnessing steady expansion driven by increasing biopharmaceutical production, stringent regulatory requirements for product safety, and growing investments in vaccine, cell therapy, and biologics development.

The rising prevalence of chronic and infectious diseases worldwide, coupled with the growing demand for biologics, biosimilars, vaccines, and advanced therapy medicinal products, is encouraging pharmaceutical and biotechnology companies to adopt comprehensive biological safety testing solutions. Sterility testing, endotoxin testing, mycoplasma detection, adventitious agent testing, and viral safety assessments have become critical components of product development and quality assurance processes, ensuring regulatory compliance and patient safety while supporting the commercialization of innovative therapeutics.

Key Market Trends & Insights

• North America dominated the Biological Safety Testing Products and Services Market with the largest revenue share of 38.62% in 2025, supported by a strong biopharmaceutical industry presence, advanced testing infrastructure, and stringent regulatory compliance requirements.
• The Kits and Reagents segment led the market with a 48.63% share in 2025, driven by their recurring consumption across biological safety testing workflows and widespread use in sterility, endotoxin, mycoplasma, and bioburden testing.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.1% from 2026 to 2033, fueled by expanding biopharmaceutical manufacturing capacity, increasing vaccine production, and growing investments in biotechnology research across China, India, South Korea, and Japan.
• Services are the fastest-growing product type, projected to register a CAGR of 8.4%, reflecting the surge in outsourcing of biological safety testing activities by pharmaceutical and biotechnology companies
• The Sterility Test segment dominated the test category with a 27.84% revenue share in 2025, led by its critical role in ensuring that pharmaceutical products, vaccines, biologics, and medical therapies remain free from viable microbial contamination.
• Vaccines and Therapeutics accounted for 39.74% of the market, preferred by the large-scale production of biologics, monoclonal antibodies, biosimilars, and preventive vaccines.
• The Gene Therapy segment is the fastest-growing application category, with a CAGR of 9.2%, driven by the increasing clinical development and commercialization of gene-based treatments.

Market Size & Forecast

• Global Market Value (2025): USD 5.84 Billion
• Expected Market Value (2033): USD 14.66 Billion
• Forecast CAGR (2026–2033): 12.20%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Biological Safety Testing Products and Services Market Segmentation

Biological Safety Testing Products and Services Market Trends

Trend: Growing Adoption of Rapid Microbiological Testing Technologies

Biopharmaceutical manufacturers are increasingly adopting rapid biological safety testing technologies to accelerate product release timelines, improve contamination detection accuracy, and enhance manufacturing efficiency without compromising regulatory compliance. The integration of automation, molecular diagnostics, and real-time monitoring systems enables faster identification of microbial contaminants and process deviations. Contract testing laboratories and pharmaceutical companies are similarly leveraging advanced testing platforms to support large-scale biologics production through standardized, data-driven quality control workflows, while digital technologies create streamlined environments that closely align with modern regulatory expectations.

For instance, in June 2024, the Merck KGaA Life Science business expanded its rapid sterility and microbial quality control capabilities, supporting faster testing workflows for biopharmaceutical manufacturers.

Biological Safety Testing Products and Services Market Dynamics

Key Market Driver: Rising Biopharmaceutical and Advanced Therapy Production

The rapid expansion of biologics, vaccines, biosimilars, and advanced therapy medicinal products has created substantial demand for biological safety testing products and services that can verify sterility, purity, and product safety throughout development and manufacturing. Pharmaceutical companies, biotechnology firms, and contract development organizations are deploying comprehensive testing solutions as a core component of their quality assurance strategy, reducing contamination risks, accelerating regulatory approvals, and improving patient safety.

For instance, in March 2024, Charles River Laboratories expanded biologics testing capabilities to support growing global demand for cell and gene therapy safety assessment services.

Key Restraint/Challenge: Complex Regulatory Requirements and Validation Processes

A significant restraint in the Biological Safety Testing Products and Services Market is the complex regulatory framework governing product safety evaluation. Modern testing programs integrate multiple assays for sterility, endotoxins, mycoplasma, and viral contaminants, requiring extensive validation, documentation, and ongoing compliance management. The total operational burden extends to method qualification, regulatory inspections, and staff training requirements, making implementation challenging for smaller biotechnology companies, academic laboratories, and resource-constrained organizations.

For instance, evolving guidance from the U.S. Food and Drug Administration and the European Medicines Agency continues to require additional validation efforts for advanced biological products and novel testing methodologies.

Key Market Opportunity: Expansion of Cell and Gene Therapy Safety Testing

The expansion of cell and gene therapy development presents a significant market opportunity. Advanced safety testing platforms can support detection of adventitious agents, evaluate product integrity, and provide comprehensive quality analytics for highly specialized therapies. The development of automated testing workflows and next-generation analytical technologies is further improving testing efficiency, opening growth opportunities across emerging biotechnology hubs in Asia-Pacific, Latin America, and the Middle East.

For instance, in September 2024, Eurofins Scientific expanded specialized cell and gene therapy testing services to address increasing demand from global biopharmaceutical developers.

Biological Safety Testing Products and Services Market Scope

The biological safety testing products and services market is segmented on the basis of product, test, application, and end-use.

• By Product

On the basis of product, the Biological Safety Testing Products and Services Market is segmented into kits and reagents, instruments, and services. The Kits and Reagents segment dominated the market with a 48.63% share in 2025, owing to their recurring consumption across biological safety testing workflows and widespread use in sterility, endotoxin, mycoplasma, and bioburden testing. These products are essential for routine quality control procedures conducted throughout biopharmaceutical manufacturing and product development. The segment benefits from increasing biologics production, which requires frequent testing at multiple stages of the manufacturing process. Continuous innovation in assay sensitivity, accuracy, and turnaround time is further supporting adoption. Regulatory agencies mandate validated testing procedures, increasing the demand for high-quality reagents and testing kits. Their indispensable role in ensuring product safety and compliance continues to strengthen market leadership.

The Services segment is projected to register the fastest growth at a CAGR of 8.4% from 2026 to 2033, driven by increasing outsourcing of biological safety testing activities by pharmaceutical and biotechnology companies. Many manufacturers prefer specialized contract testing providers to reduce operational costs and gain access to advanced testing expertise. Growing complexity in biologics, cell therapies, and gene therapies is increasing the need for sophisticated testing capabilities. Service providers offer scalable solutions, regulatory support, and faster turnaround times that are difficult to achieve internally. Expansion of contract research and manufacturing organizations is further accelerating market growth. Increasing regulatory scrutiny and demand for specialized testing methods continue to create strong opportunities for outsourced service providers.

• By Test

On the basis of test, the Biological Safety Testing Products and Services Market is segmented into endotoxin test, sterility test, residual host contamination detection tests, cell line authentication and characterization tests, bioburden tests, adventitious agent detection test, and others. The Sterility Test segment dominated the market with a 27.84% share in 2025 due to its critical role in ensuring that pharmaceutical products, vaccines, biologics, and medical therapies remain free from viable microbial contamination. Regulatory authorities worldwide require sterility testing before product release, making it a mandatory quality assurance process. The growing production of injectable drugs and biologics is significantly supporting demand. Advances in rapid sterility testing technologies are improving efficiency and reducing testing timelines. Pharmaceutical manufacturers increasingly prioritize contamination prevention to protect patient safety and maintain compliance. The universal application of sterility testing across multiple product categories continues to reinforce its dominant market position.

The Adventitious Agent Detection Test segment is expected to witness the fastest growth at a CAGR of 8.8% from 2026 to 2033, driven by increasing development of advanced biologics, vaccines, and cell-based therapies. These tests are essential for identifying unintended viral, bacterial, fungal, or mycoplasma contaminants that may compromise product safety. Growing regulatory emphasis on comprehensive risk assessment is boosting adoption. Technological advancements in molecular diagnostics and next-generation sequencing are improving detection capabilities. The expansion of gene therapy and regenerative medicine pipelines is further increasing testing requirements. Rising focus on ensuring safety in complex biological products is expected to accelerate growth throughout the forecast period.

• By Application

On the basis of application, the Biological Safety Testing Products and Services Market is segmented into blood and blood-based products, gene therapy, tissue and tissue-based products, vaccines and therapeutics, stem cells, and others. The Vaccines and Therapeutics segment dominated the market with a 39.47% share in 2025, driven by the large-scale production of biologics, monoclonal antibodies, biosimilars, and preventive vaccines. These products require extensive biological safety testing throughout development, manufacturing, and commercialization stages. Increasing prevalence of chronic and infectious diseases is supporting ongoing demand for advanced therapeutics. Regulatory requirements for product safety and efficacy continue to strengthen testing adoption. Pharmaceutical companies invest heavily in quality control programs to minimize contamination risks. The segment also benefits from expanding global immunization programs and biologics development activities, maintaining its leadership position.

The Gene Therapy segment is projected to register the fastest growth at a CAGR of 9.2% from 2026 to 2033 due to increasing clinical development and commercialization of gene-based treatments. Gene therapy products require highly specialized safety testing procedures to detect viral contaminants, residual impurities, and adventitious agents. Growing investment in rare disease and oncology research is expanding the development pipeline. Regulatory agencies have established stringent testing standards for advanced therapy medicinal products, increasing demand for biological safety assessments. Technological advancements in genetic engineering and vector development are further supporting market expansion. The rapid evolution of personalized medicine is expected to drive substantial growth in this segment.

• By End-Use

On the basis of end-use, the Biological Safety Testing Products and Services Market is segmented into pharmaceuticals and biotechnology companies, contract development and manufacturing companies, research and academia, and others. The Pharmaceuticals and Biotechnology Companies segment led the market with a 46.35% share in 2025, driven by extensive investments in biologics, vaccines, biosimilars, and advanced therapeutic products. These organizations conduct biological safety testing throughout research, development, manufacturing, and product release processes. Increasing regulatory compliance requirements are encouraging the adoption of advanced testing technologies. The segment benefits from growing R&D expenditure and expansion of biopharmaceutical manufacturing facilities worldwide. Continuous innovation in drug development is creating sustained demand for safety testing solutions. Their central role in bringing biological products to market continues to support segment dominance.

The Contract Development and Manufacturing Companies (CDMOs) segment is expected to witness the fastest growth at a CAGR of 8.7% from 2026 to 2033, fueled by increasing outsourcing trends across the pharmaceutical and biotechnology industries. Drug developers are increasingly partnering with CDMOs to access specialized expertise, advanced testing infrastructure, and regulatory support services. Growing demand for cost-effective and scalable manufacturing solutions is accelerating outsourcing activities. Expansion of biologics and cell therapy production is further increasing the need for third-party testing capabilities. CDMOs offer integrated development, manufacturing, and quality assurance services that improve operational efficiency. Rising complexity of biologic products and increasing global production capacity are expected to drive strong growth in this segment.

Biological Safety Testing Products and Services Market Regional Analysis

North America dominated the Biological Safety Testing Products and Services Market with the largest revenue share of 38.62% in 2025, supported by a strong biopharmaceutical industry presence, advanced testing infrastructure, and stringent regulatory compliance requirements. The region also benefits from extensive investments in biologics development, advanced testing technologies, and growing adoption of specialized safety testing solutions across vaccines, cell therapies, gene therapies, and biologic manufacturing applications. Increasing focus on product quality assurance and regulatory compliance, coupled with expanding research activities and therapeutic innovation, continues to strengthen North America’s leadership position in the global market.

U.S. Biological Safety Testing Products and Services Market Insight

The U.S. biological safety testing products and services market is witnessing strong growth due to rising investments in biopharmaceutical research, biologics manufacturing, and advanced therapy development programs. The country’s mature pharmaceutical and biotechnology ecosystem, along with increasing adoption of rapid microbiological testing, molecular diagnostics, and automated quality control systems, is driving demand across commercial and research applications. In addition, growing emphasis on regulatory compliance, product safety assurance, and contamination risk management is accelerating the adoption of biological safety testing solutions across pharmaceutical manufacturers and contract service providers.

Europe Biological Safety Testing Products and Services Market Insight

The Europe biological safety testing products and services market remains a major contributor to global revenue, driven by strong regulatory frameworks, technological innovation, and high demand for advanced quality assurance solutions. The widespread use of biological safety testing in biologics manufacturing, vaccine production, and cell therapy development is supporting market expansion across the region. Increasing investments in rapid testing technologies, coupled with strict product safety requirements and a highly developed life sciences industry, continue to enhance the adoption of biological safety testing products and services throughout Europe.

U.K. Biological Safety Testing Products and Services Market Insight

The U.K. biological safety testing products and services market is experiencing steady growth, supported by rising adoption of advanced testing technologies in pharmaceutical development, biologics manufacturing, and research applications. Increasing investments in laboratory infrastructure and growing demand for efficient, regulatory-compliant quality control solutions are contributing to market growth. Furthermore, integration of automation, molecular testing platforms, and digital laboratory technologies is improving testing accuracy and operational efficiency, positioning the U.K. as a key innovation hub in the biological safety testing industry.

Germany Biological Safety Testing Products and Services Market Insight

The Germany biological safety testing products and services market is expanding steadily due to the country’s strong pharmaceutical manufacturing base, advanced research capabilities, and increasing adoption of next-generation testing technologies. Pharmaceutical companies, biotechnology firms, and contract laboratories are increasingly utilizing biological safety testing solutions for contamination detection, product validation, and quality assurance activities. Continuous advancements in rapid testing methods, automation technologies, and analytical platforms, along with strong government focus on healthcare innovation and product safety, are further driving market growth in Germany.

Asia-Pacific Biological Safety Testing Products and Services Market Insight

The Asia-Pacific biological safety testing products and services market is expected to witness rapid growth, driven by expanding biopharmaceutical production, increasing healthcare investments, and rising laboratory infrastructure development across countries such as China, India, and Japan. Growing awareness regarding product safety, rising adoption of advanced testing technologies, and increasing demand for scalable and cost-effective quality control solutions are supporting regional market expansion. In addition, the growing presence of biotechnology research centers and pharmaceutical manufacturing facilities is accelerating adoption across commercial and academic sectors.

Japan Biological Safety Testing Products and Services Market Insight

The Japan biological safety testing products and services market is witnessing consistent growth due to rising investments in biologics development, pharmaceutical innovation, and healthcare quality initiatives. Pharmaceutical manufacturers, biotechnology companies, and research institutes are increasingly adopting advanced testing solutions for product validation, contamination detection, and regulatory compliance purposes. Moreover, increasing integration of automation technologies and the country’s focus on safe and high-quality therapeutic products are further contributing to market growth.

China Biological Safety Testing Products and Services Market Insight

The China biological safety testing products and services market is growing rapidly, driven by expanding biopharmaceutical manufacturing capacity, increasing healthcare infrastructure development, and rising government focus on drug quality and safety standards. Growing adoption of automated testing systems and advanced analytical platforms across pharmaceutical, biotechnology, and research sectors is significantly boosting market demand. In addition, rising investments in biologics production, increasing awareness regarding regulatory compliance, and rapid technological advancements are positioning China as one of the fastest-growing markets for biological safety testing products and services globally.

Biological Safety Testing Products and Services Market Share

The biological safety testing products and services industry is primarily led by well-established companies, including:

• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Charles (U.S.)
• Eurofins Scientific SE (Luxembourg)
• Sartorius AG (Germany)
• Lonza Group AG (Switzerland)
• SGS SA (Switzerland)
• WuXi AppTec Co., Ltd. (China)
• WuXi Biologics Inc. (China)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher (U.S.)
• QIAGEN (Netherlands)
• Promega Corporation (U.S.)
• Pacific BioLabs (U.S.)
• Nelson Laboratories, LLC (U.S.)
• Microbac Laboratories, Inc. (U.S.)
• Creative Bioarray (U.S.)
• BioReliance Corporation (U.S.)
• Toxikon Corporation (U.S.)

Latest Developments in Biological Safety Testing Products and Services Market

• In September 2025, FUJIFILM Wako Pure Chemical Corporation announced the launch of its RiboNAT™ Rapid Sterility Test, a novel testing kit designed to accelerate sterility testing for cell therapies. The solution addresses the growing need for rapid microbial safety assessment in advanced therapies that must be administered shortly after production. By significantly reducing testing timelines compared with conventional sterility methods, the launch supports faster product release while enhancing patient safety and manufacturing efficiency
• In May 2024, Merck KGaA announced the launch of M-Trace® Software & Mobile App, a digital solution designed to improve sterility testing workflows and microbial quality control processes. The platform provides real-time data traceability, automated documentation, and enhanced regulatory compliance for biological safety testing operations. This development highlights the industry's increasing focus on digitalization and error reduction in pharmaceutical quality assurance environments
• In April 2024, Merck KGaA launched the Aptegra™ CHO Genetic Stability Assay, the first validated all-in-one assay designed to accelerate biosafety testing for biologics manufacturing. The platform combines multiple genetic stability assessments into a single test, reducing testing time and simplifying regulatory compliance requirements. The launch reflects growing demand for advanced analytical tools that improve efficiency and reliability in biologics development and commercialization
• In November 2023, Merck KGaA expanded its Biologics Testing Center in Shanghai, China, adding new biosafety laboratory capacity to support cell line characterization and lot-release testing services. The expansion enhances local access to biological safety testing solutions for biopharmaceutical developers from preclinical development through commercialization. This investment demonstrates the growing importance of regional testing infrastructure in supporting global biologics manufacturing
• In May 2023, Merck KGaA announced a €35 million investment in biosafety testing facilities in Scotland, expanding testing capacity across its Glasgow and Stirling sites. The investment was aimed at meeting rising global demand for biosafety testing services used in drug development and commercialization. The expansion also included workforce growth and additional laboratory capabilities, reinforcing the company's commitment to supporting the rapidly growing biologics and advanced therapies sector

SKU-56033